Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report.
- Author:
Ziqiang WU
1
;
Jingjing HUANG
;
Srinivas SADDA
Author Information
- Publication Type:Case Reports
- MeSH: Adult; Angiogenesis Inhibitors; administration & dosage; pharmacology; therapeutic use; Antibodies, Monoclonal; administration & dosage; pharmacology; therapeutic use; Antibodies, Monoclonal, Humanized; Bevacizumab; Choroidal Neovascularization; drug therapy; Female; Humans; Pregnancy; Pregnancy Complications; drug therapy; Treatment Outcome
- From:Annals of the Academy of Medicine, Singapore 2010;39(2):143-145
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTIONThis study reports a case of bevacizumab administered to treat choroidal neovascularisation in a woman later discovered to be pregnant.
CLINICAL PICTUREA 25-year-old pregnant woman developed myopic choroidal neovascularisation in both eyes.
TREATMENTBoth eyes were treated with a total of 3 intravitreal injections of bevacizumab sequentially.
OUTCOMEVision improved significantly in both eyes. There were no evident pregnancy-related complications at 1 year postpartum.
CONCLUSIONAlthough anti-vascular endothelial growth factor (VEGF) therapy did not result in any detectable short-term adverse event in this mother and baby, the potential toxicity of these agents must be carefully considered in pregnant patients.
